Optima is launching a plasma scanner in the near future, a step that it says will help doctors diagnose more accurately the condition of patients who have the disease.
The new technology is part of the company’s efforts to expand into the healthcare industry, with a focus on the treatment of cancer.
The company has previously focused on plasma scans for cancer patients, and this will be its first major foray into healthcare.
Optima, which is based in Perth, is one of the largest plasma scanner manufacturers in the world.
“In cancer, there are a lot of different types of cancers, and we’re looking at many different types,” Mr Lachlan said.
The company’s plasma scanning technology has been used in Australia, where it’s been used to diagnose lung cancer. “
This is something that we’ve been working on for the last 10 years.”
The company’s plasma scanning technology has been used in Australia, where it’s been used to diagnose lung cancer.
But it’s also used in cancer research around the world, and the company says it can help doctors and patients understand how cancer is progressing and how they might respond to different treatments.
The scanning technology works by taking an image of the patient’s blood and using that to create a 3D image of their blood vessels.
The result is then sent back to a lab, where the researchers can see how the cells are progressing.
The technology is currently used in a number of clinical trials, including for a rare blood cancer called non-Hodgkin lymphoma.
The scanner’s biggest drawback is that it only works on certain types of cells, which can vary widely.
The team says it’s looking into improving the technology in the next few years, and they have the capacity to expand to the healthcare sector.
Optimas technology, which uses a laser scanner, was first introduced in 2015, but has since grown into a company with about 200 employees.
It was founded by entrepreneur Mark Jellicoe, who founded the company in 2009.
Mr Jellis said the technology could potentially be used in more than just lung cancer, and said it could also be used to screen for other diseases as well.
“We think we’re very close to being able to scan for all kinds of cancers,” Mr Jells said.
He said the company had been working with doctors in a few centres to bring the technology to life, and he was optimistic that patients would be able to access it soon.
“The scanner’s been developed for lung cancer but it could potentially work for other cancers,” he said.
“It’s still very early days but it’s a big step forward in the right direction.”
Opta is also looking to expand in the healthcare space.
The Australian Cancer Society has also recently signed on to use the scanner for testing patients.
“I think the biggest challenge for us is the fact that it is still a very nascent technology, and in some ways the potential is there to be able use it in other diseases,” Dr Jennifer Anderton, the director of research and clinical development at the ACS, said.
She said the scanner was also being tested in the US, where Optima currently has a contract with a health insurance company.
“[It] will be very important for the ACS to test it in a wide range of patients,” Dr Ander, who also runs the ACS’s Cancer Research and Treatment Center in Melbourne, said, adding that the technology was also working in the clinic.
Optas is also exploring the possibility of bringing the technology into Australia.
“It’s really exciting for us because it’s such a big industry in Australia that we’re so focused on,” Dr Lachlans said.
The project is still in the early stages and the scanning technology is still developing, but Dr Lathan said he believed it would be an affordable way to get the technology up and running.
“If it’s something that’s affordable and we can do it in Australia in two to three years, we will,” he told The World Today.
He said that the scanning device was being developed to be used at clinics and hospitals, but could also help doctors in the hospital.
“You can look into the patient, you can make some diagnoses and then you can look after them,” Dr Jelles said.